Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Toripalimab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Jan 2019 New trial record